Bioventus Inc.
BVS
$6.55
$0.121.87%
NASDAQ
| 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.60% | 11.89% | 10.40% | 5.14% | 1.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.60% | 11.89% | 10.40% | 5.14% | 1.72% |
| Cost of Revenue | 2.61% | 0.49% | -1.87% | -4.84% | -2.44% |
| Gross Profit | 11.75% | 18.29% | 17.65% | 11.00% | 4.06% |
| SG&A Expenses | 7.14% | 8.14% | 5.78% | -0.92% | -7.67% |
| Depreciation & Amortization | -11.55% | -13.46% | -3.59% | 0.21% | -1.80% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.38% | 4.84% | 2.19% | -3.19% | -7.05% |
| Operating Income | 89.30% | 1,789.24% | 363.49% | 264.69% | 174.70% |
| Income Before Tax | -79.66% | 59.11% | 59.93% | 77.00% | 90.20% |
| Income Tax Expenses | -653.16% | -6,327.06% | 34.90% | 83.65% | 102.89% |
| Earnings from Continuing Operations | -49.40% | 63.50% | 61.80% | 75.83% | 88.03% |
| Earnings from Discontinued Operations | -- | -- | 100.00% | 100.00% | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 71.12% | -57.60% | -62.21% | -78.12% | -90.29% |
| Net Income | -43.87% | 78.33% | 78.14% | 85.06% | 92.33% |
| EBIT | 89.30% | 1,789.24% | 363.49% | 264.69% | 174.70% |
| EBITDA | 19.45% | 49.56% | 29.65% | 40.08% | 73.06% |
| EPS Basic | -40.68% | 78.98% | 78.77% | 85.46% | 92.46% |
| Normalized Basic EPS | 242.42% | 4,202.50% | 140.16% | -72.43% | -166.88% |
| EPS Diluted | -40.68% | 78.98% | 78.77% | 85.46% | 92.46% |
| Normalized Diluted EPS | 242.42% | 4,202.50% | 140.16% | -72.43% | -166.88% |
| Average Basic Shares Outstanding | 3.54% | 3.01% | 2.55% | 2.05% | 1.88% |
| Average Diluted Shares Outstanding | 3.54% | 3.01% | 2.55% | 2.05% | 1.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |